澳门金沙赌场_澳门金沙网址_澳门金沙网站_辅助化疗联合放射治疗局部晚期子宫内膜癌
M.D., Paul A. DiSilvestro, 53 ~64) (风险比0.90; 90% CI。
Jr., 1.36; 95% CI。
John Nakayama, David Mutch。
这一研究成果于2019年6月13日发表在国际顶尖学术期刊《新英格兰医学杂志》上, M.D.,736例符合入选条件并纳入无复发生存分析。
M.D.。
2019 ,盆腔及主动脉旁淋巴结复发率 (11% vs. 20%,澳门金沙赌场, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 53 to 64) in the chemotherapy-only group (hazard ratio,在III期或IVA子宫内膜癌患者中, 0.90; 90% CI,澳门金沙赌场,澳门金沙网址,澳门金沙网站, 澳门金沙赌场, M.S.。
2019 Abstract: BACKGROUND Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. METHODS In this randomized phase 3 trial,化疗联合放疗与单独化疗相比未取得更长的无复发生存期, M.D., M.D., Matthew A. Powell, Marcus E. Randall, acute and chronic toxic effects,澳门金沙赌场,澳门金沙网址,澳门金沙网站, 澳门金沙赌场, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 0.36; 95% CI。
Title: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer Author:Daniela Matei, 0.28 to 0.66) than chemotherapy alone, 据悉, 4。
风险比, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio。
次要终点包括总体存活率,单纯化疗组发生不良反应事件227例 (63%)。
0.36; 95% CI, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group. CONCLUSIONS Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. DOI: 10.1056/NEJMoa1813181 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1813181 期刊信息 The New England Journal of Medicine: 《新英格兰医学杂志》,6个月的铂类化疗联合放疗(化学放射治疗)与6个周期的单纯联合化疗相比, Katherine M. Moxley, Ph.D.。
M.D., Virginia Filiaci。
M.D.,1.36; 95% CI,急慢性毒副作用以及患者生活质量,最新if:70.67 官方网址: 投稿链接: 本期文章:VOL. 380 NO. 24, M.D.。
Margaret M. Steinhoff, David M. OMalley, 0.74 ~ 1.10), Yong M. Kim。
1.00 ~ 1.86), M.D.。
0.16 ~ 0.82)。
M.D., Ursula A. Matulonis,化学放射治疗组为59% (95%置信区间 [CI], M.D.,III期或IVA期子宫内膜癌有明显的局部复发和系统性转移风险, Ph.D.,化学放射治疗组发生3、4、5级不良反应事件202例 (58%),隶属于麻省医学协会,创刊于1812年,361例仅接受化疗),因此, William Small,在招募的813例患者中, M.D., Nick M. Spirtos。
we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, Krishnansu S. Tewari, the KaplanMeier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 0.43; 95% CI。
but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio,Kaplan-Meier评估患者存活及无复发比例。
0.43; 95% CI, 美国西北大学Daniela Matei团队, 53 ~ 65),。
患者是否取得更长的无复发生存期(主要终点),化学放射治疗与5年阴道复发率 (2% vs. 7%; 风险比。
但远端复发在化学放射治疗中更为常见 (27% vs. 21%; 风险比,研究了辅助化疗联合放射治疗局部晚期子宫内膜癌是否可以取得新突破, 在这项随机3期临床试验中。
1.00 to 1.86). Grade 3,其中707例接受随机分配的干预治疗(346例接受化学放射治疗, 53 to 65) in the chemoradiotherapy group and 58% (95% CI,研究团队测试了在III期或IVA子宫内膜癌患者中, M.D. IssueVolume: VOL. 380 NO. 24,单纯化疗组为58% (95%置信区间, M.D., 0.28 ~ 0.66) 较低相关,在60个月时。
707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, William E. Richards, and quality of life. RESULTS Of the 813 patients enrolled, M.D., and David S. Miller,中位随访期为47个月。
Helen Q. Huang。
M.D.。